When health authorities in the Republic of Ireland reversed an initial rejection and approved state funding for Skyclarys (omaveloxolone), the sigh of relief across the Irish Sea was palpable. At the heart of that triumph was the heartbreaking yet relentless crusade of Craig Coady. Having lost his 13-year-old son, Rory, to Friedreich’s ataxia, Craig was forced to open up his deeply personal loss to the public to prevent his surviving 16-year-old son, Paudie, from suffering the same fate.
The Coady family’s agony—a father begging for a drug that could slow his remaining child’s decline—finally pierced institutional rigidity. It proved that human compassion, stubborn advocacy, and political leadership can force health services and pharmaceutical firms to find common ground.
Yet, for families across Northern Ireland, England, Scotland, and Wales, the victory in Dublin serves as a bitter reminder of an unjust geography. A short journey across the Irish border now separates those who are granted a lifeline from those left to watch their bodies slowly fail them without options.
The Human Reality of Friedreich’s Ataxia
Friedreich’s ataxia is a cruel, relentless neurodegenerative condition that targets young people, robbing them step by step of their independence, motor skills, speech, and mobility, while often damaging the heart.
Skyclarys is not a silver bullet, nor does it claim to be a complete cure. What it offers—proven through clinical trials—is time. It slows disease progression by up to 50%, preserving a person’s ability to walk, use their hands, and hold a conversation with loved ones for years longer than nature would otherwise allow.
THE RACE AGAINST NEUROLOGICAL DECLINE
Without Intervention ──► Rapid loss of mobility ──► Speech impairment ──► Severe disability
With Skyclarys ──► Progression slowed ~50% ──► Function retained ──► Independence preserved
A Systemic Divide: Ireland vs. The UK
While European and UK drug regulators have long declared Skyclarys safe and effective, the mechanics of public reimbursement have created a profound disparity.
| Jurisdiction | Status of Skyclarys | Mechanism |
| Republic of Ireland | Approved & Funded | Reimbursed via HSE following intensive pricing negotiations with manufacturer Biogen. |
| Northern Ireland | Unavailable | Dependent on NHS appraisal frameworks despite sharing an island with approved access. |
| England & Wales | Stalled in Review | Pending guidance from NICE; no routine interim funding mechanism active. |
| Scotland | Restricted Access | Rejected for routine use by SMC; accessible only via complex individual funding pathways. |
The Cost of Delay: Why UK Leadership Must Act Now
In health technology assessments, bureaucratic delays are calculated in financial metrics, budget impact models, and incremental cost-effectiveness ratios. But for people living with Friedreich’s ataxia, delay is measured in lost movement, quieted voices, and stolen milestone years.
Every month that UK authorities and manufacturer representatives spend locked in price impasses is a month of irreversible physical decline for patients.
The lesson of the Coady case in Ireland is clear: where there is political courage and human empathy, administrative barriers can be overcome. UK health ministers, the NHS, and pharmaceutical leaders must look across the border, recognize the moral necessity before them, and grant patients the access they urgently need.
Friedreich’s Ataxia: Families’ final push for access to Skyclarys
This report documents the emotional public campaign led by Craig Coady and Irish families prior to the HSE’s approval, illustrating the exact grass-roots pressure that UK advocates are currently mobilizing to replicate.
Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, England on Wikipedia by Tony Hisgett
